Created with Sketch.
Treating Blood Cancers
28 minutes | Nov 16, 2022
Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part II
Daphne Friedman, MD, Durham VA Health Care System, Durham, NC Recorded on October 20, 2022 In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.
25 minutes | Oct 27, 2022
AML: Insights, Updates, and Takeaways
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 7, 2022 Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.
16 minutes | Oct 14, 2022
Insights from Attending the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting
Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 30, 2022 Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here!
35 minutes | Sep 20, 2022
What’s New in the Treatment of BPDCN?
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on September 6, 2022 Join us as Dr. Naveen Pemmaraju from MD Anderson Cancer Center, returns to discuss blastic plasmacytoid dendritic cell neoplasms (BPDCN)! In this episode, Dr. Pemmaraju provides an overview of BPDCN, including major updates in the treatment of the disease since our last episode on this topic in 2019. What is BPDCN? How is it treated? Is it curable? What resources are available for patients living with this rare disease? Join the conversation and learn more today! This podcast episode is supported by Stemline Therapeutics, Inc.
37 minutes | Aug 11, 2022
Mastocytosis: Insight into a Rare Blood Cancer
Jason Gotlib, MD, Stanford University School of Medicine, Palo Alto, CA Recorded on July 19, 2022 Mastocytosis is a rare and complex disease. In this special episode, Dr. Jason Gotlib from the Stanford University School of Medicine in Palo Alto, CA, discusses an overview of the disease, including its subtypes, clinical presentations, and treatment related toxicities. Dr. Gotlib addresses the importance of second opinions, collaborating with multidisciplinary specialists to treat patients, unmet needs and exciting new and emerging treatments. Learn more about the future of mastocytosis by listening to this episode today! This podcast episode is supported by Blueprint Medicines Corporation.
32 minutes | Jul 20, 2022
The Role of Genomics in Treating Blood Cancers
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ Recorded on June 30, 2022 In this episode, Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, joins Dr. Ken Miller to breakdown the complex and complicated nature of genomics and molecular profiling. He discusses the role of molecular profiling in treating blood cancers, explains how we integrate genomics into the standard of care for people living with cancer, the potential of false negatives, provides examples of clinical applications, financial implications, and resources for patients. Tune in to the conversation today! This podcast episode is supported by Blueprint Medicines Corporation.
40 minutes | Jun 23, 2022
Insights into Pediatric Survivorship for the HCP
Kevin C. Oeffinger, MD, FASCO, Duke University Medical Center, Durham, NC Recorded on June 9, 2022 Children diagnosed with cancer are a heterogenous population experiencing different cancer diagnoses and therapies. Each journey presents its own physical, emotional, and psychosocial challenges that healthcare providers need to be attentive to. In this episode, Dr. Kevin Oeffinger, from Duke University in Durham, North Carolina, joins us to discuss the history of pediatric survivorship, physical, long-term, and late effects of treatment, including fertility considerations, strategies to support the survivor through psychosocial and cognitive effects, following a survivorship care plan, symptom monitoring, follow-up care, and so much more. Tune in to this important conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc.
42 minutes | Jun 9, 2022
PedAL: First-of-Its-Kind Global Master Clinical Trial for Pediatric Acute Leukemia
Gwen L. Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on May 20, 2022 Through the LLS Children’s Initiative, The Leukemia & Lymphoma Society (LLS) is setting out to fundamentally change how children with blood cancer are treated and cared for. For children and their families, LLS provides free education, support services, financial assistance, advocacy efforts, and has increased its research investments in childhood blood cancer. As part of this initiative, LLS PedAL, a first-of-its-kind global master clinical trial for pediatric acute leukemia patients, will fundamentally change how children are treated. In this episode, Dr. Gwen Nichols, EVP and Chief Medical Officer joins us to discuss PedAL, including sharing reflections on lack of pediatric ALL and AML therapies that led to the development of this master clinical trial. Dr. Nichols discusses challenges in creating pediatric therapies, the importance of data collection and creating a standard of care, and the ultimate impact PedAL will have on all clinical trials moving forward. Tune in today!
27 minutes | May 24, 2022
The Role of the Primary Care Physician in Treating Chronic Blood Cancers: Focus on Myeloma
Zalman Suldan, MD, PhD, Hackensack University Medical Center – Hackensack Meridian Health, Hackensack, NJ Recorded on May 3, 2022 The primary care physician plays an important role in the treatment of patients living with a chronic blood disorder, from early diagnosis to appropriate referral to a hematologist-oncologist, from coordination of care to goals of therapy. In this episode, we are joined by Dr. Zalman Suldan, from Hackensack Medical Center in New Jersey, who shares his unique insights as both a primary care physician and nephrologist. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
39 minutes | Apr 26, 2022
CAR T-cell Therapy in 2022: What You Need to Know Part II
Rayne H. Rouce, MD, BS, Texas Children’s Cancer Center for Cell and Gene Therapy, Houston, TX Recorded on April 8, 2022 As CAR T-cell therapy continues to evolve in new and exciting ways, new indications are approved and treatment toxicities reduced. In this episode, Dr. Rayne Rouce, from the Texas Children’s Cancer Center for Cell and Gene Therapy at Baylor College in Houston, joins us to discuss hot topics in CAR T-cell therapy, including how CAR-T has evolved over the past few years, understanding why some patients do better than others, access to treatment and overcoming logistics, shared care models with the referring physician, CAR-T in pediatric patients, communicating with patients, and so much more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company, Janssen Oncology & Legend Biotech, and Novartis Pharmaceuticals Corporation.
43 minutes | Apr 14, 2022
Everything You Need to Know About Cutaneous T-cell Lymphoma
Francine Foss, MD and John A. Zic, MD, MMHC Recorded on March 28, 2022 This informative episode covers everything you need to know about cutaneous T-cell lymphoma, from its biology, subclassifications, targeted therapy, goals of treatment, novel toxicities, and so much more! Join Dr. Ken Miller as he delves into cutaneous T-cell lymphoma with two special guests; Dr. Francine Foss from Yale University School of Medicine and Dr. John Zic from Vanderbilt University Medical Center. Learn more about cutaneous T-cell lymphoma from a 60,000 foot view, disparities in the delivery of care, and exciting new research presented at the United States Cutaneous Lymphoma Consortium Annual Meeting. Tune in today!
38 minutes | Mar 23, 2022
A Deep Dive into Myelofibrosis
Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX Recorded on February 18, 2022 In this month’s episode, Dr. Srdan Verstovsek, from MD Anderson Cancer Center in Houston, Texas, joins us to discuss myelofibrosis. What is myelofibrosis? What is our understanding of the disease? What are the deciding factors for cells to branch off into myelofibrosis and not other myeloproliferative neoplasms? Tune in as we explore myelofibrosis, including discussion on diagnosing and staging, goals and considerations for therapy, the impact of COVID-19 on treatment, and new and emerging drugs in development. This podcast episode is supported by AbbVie Inc.
33 minutes | Feb 17, 2022
Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part I
Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY Recorded on February 1, 2022 Shared decision making between patients and their healthcare team is an important component to treatment, regardless of the diagnosis. For chronic leukemias, patient worries may be intensified when doctors suggest forgoing active treatment for a watch-and-wait approach. In this episode, Dr. Jacqueline Barrientos, from the Northwell Health Cancer Institute in Lake Success, New York, highlights the importance of shared decision making with her patients. Dr. Barrientos discusses challenges that arise, shared decision making across the multidisciplinary team, navigating second opinions, long-term and late effects, and maintaining open lines of communication. Listen in on this important conversation today! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.
42 minutes | Jan 25, 2022
CAR T-cell Therapy in 2022: What You Need to Know
Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on January 4, 2022 As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, Harvard Medical School, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute in Boston, MA, discusses updates in CAR T-cell therapy, including progress in managing toxicities, barriers to treatment, CAR T structure and manufacturing, other practical issues such as determining the best treatment option for patients facing serious disease, and future directions. Tune in to learn more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company and Novartis Pharmaceuticals Corporation.
44 minutes | Jan 12, 2022
Highpoints from Attending the 2021 American Society of Hematology Conference
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 22, 2021 Each year, blood cancer professionals gather at the American Society of Hematology Annual Meeting to discuss the latest updates in blood cancer research, treatment, and clinical trials. In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, highlights the inflection points from the 63rd ASH Annual Meeting, including CAR T-cell therapy, bi-specific antibodies, and cell-free DNA. He reviews the latest data on Covid-19 and effectiveness of vaccinations in the blood cancer patient population. Tune in to this informative update today!
29 minutes | Dec 20, 2021
Updates on COVID-19 in Patients with Blood Cancer
John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks and benefits of an mRNA vaccine? What does treatment look like in both symptomatic and asymptomatic patients? How are we seeing the Omicron variant affecting this? Tune in to this important discussion today!
39 minutes | Nov 17, 2021
A Conversation on Adult Survivorship
Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, challenges to following a cancer survivorship plan, the importance of follow-up care coordination, and how the COVID-19 pandemic has impacted survivorship care. Join us today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.
42 minutes | Oct 19, 2021
The Advanced Practice Provider’s Role in Treating Newly Diagnosed Patients with Myeloma
Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, NY Recorded on October 1, 2021 Advanced practice providers, nurses, and other members of the multidisciplinary healthcare team play an important role in treating and supporting newly diagnosed myeloma patients. In this month’s episode, Daniel Verina, DNP, ACNP-BC, Acute Care Nurse Practitioner, Multiple Myeloma Program, at the Mount Sinai Medical Center in New York, shares his perspective into treating newly diagnosed myeloma patients, including how to navigate questions about embarking on the treatment journey, potential side effects, and survival rates. He shares his thoughts on how to best support both the patient and caregiver, navigating discussion surrounding clinical trials, and what challenges lie ahead. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
39 minutes | Oct 11, 2021
The Physician’s Role in Treating Newly Diagnosed Patients with Myeloma
Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon. This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.
28 minutes | Sep 30, 2021
Clinical Trials: A Healthcare Professional’s Perspective
Lorenzo Falchi, MD and Leah Szumita, MS, RN, CCRN, ACNS-BC Recorded on August 5, 2021 Clinical trials are the foundation of advancing treatment options. Understanding their importance, dispelling myths and fears about enrollment, and acknowledging disparities in access can help providers educate their patients and discuss treatment in a clinical trial as an option at any point in the patient’s cancer journey. In this episode, we welcome special guest host Leah Szumita, MS, RN, CCRN, ACNS-BC, Director of The Leukemia & Lymphoma Society’s Clinical Trial Support Center as she speaks with Lorenzo Falchi, MD, Assistant Attending, Lymphoma Service, Memorial Sloan-Kettering Cancer Center in New York City, about the importance of clinical trials, understanding patient concerns, barriers to participation and strategies to overcome these barriers, and how clinical trials have been impacted by COVID-19.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2022